Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D002207:Capreomycin / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011188:Potassium / Q000097:blood; D012293:Rifampin / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced; D014792:Visual Acuity
D000995:Antitubercular Agents; D002207:Capreomycin; D004977:Ethambutol; D000410:Alanine Transaminase; D001663:Bilirubin; D011188:Potassium; D012293:Rifampin